Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 1/20 | 0.48 |
| ▸ | ITPR3 | Q14573 | 8/20 | 0.46 |
| ▸ | ITPR2 | Q14571 | 4/20 | 0.46 |
| ▸ | ITPR1 | Q14643 | 4/20 | 0.46 |
| ▸ | INPP5A | Q14642 | 3/20 | 0.44 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21425733 | 0.86 | ITPR3 (0.46) | SMPD1ITPR3ITPR2ITPR1INPP5A | |
| SCHEMBL19798476 | 0.82 | HSD11B1 (0.35) | SMPD1 | |
| SCHEMBL6862681 | 0.80 | HSD11B1 (0.35) | — | |
| Phytic Acid SCHEMBL9741350 | 0.73 | ITPR3 (0.77) | SMPD1ITPR3ITPR2ITPR1INPP5A | |
| Phytic Acid SCHEMBL17006482 | 0.73 | ITPR3 (0.77) | SMPD1ITPR3ITPR2ITPR1INPP5A | |
| Phytate SCHEMBL136587 | 0.73 | ITPR3 (0.77) | SMPD1ITPR3ITPR2ITPR1INPP5A | |
| SCHEMBL8467566 | 0.73 | ITPR3 (0.77) | SMPD1ITPR3ITPR2ITPR1INPP5A | |
| Phytic Acid SCHEMBL1681701 | 0.73 | ITPR3 (0.77) | SMPD1ITPR3ITPR2ITPR1INPP5A | |
| Phytic Acid SCHEMBL9164308 | 0.73 | ITPR3 (0.77) | SMPD1ITPR3ITPR2ITPR1INPP5A | |
| Phytic Acid SCHEMBL15374707 | 0.73 | ITPR3 (0.77) | SMPD1ITPR3ITPR2ITPR1INPP5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2018-01-25 | — | — | US | disclosed |
| EP-1155143-A1 | DETERMINATION OF NUCLEASE ACTIVITY | Zetatronics Limited (GB) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000049172-A1 | DETERMINATION OF NUCLEASE ACTIVITY | ZETATRONICS LIMITED (GB) | 2000-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | IDO1, IDO2, TDO2 | SMPD1 441/4885ITPR3 2324/4885ITPR2 2229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.